- Corporate
- The share
- Press releases
- Financial calendar
- Financial reports
- Financial reports – ESEF
- Prospectus and material offerings
- Financial presentations
- Corporate governance
- Analyst Coverage
- Code of Conduct
- Environmental Policy
- Code of Conduct for Suppliers
- Privacy policy
- Contact us
- Subscribe
- Thank you
- Error
Clarification of XVIVO Perfusion’s rights to Professor Stig Steen’s media for the preservation and evaluation of organs
Due to the insufficient information that Vivoline Medical has distributed in a Memorandum (including supplementary information that was recently published) ahead of its planned new share issue and listing on AktieTorget, XVIVO Perfusion feels obliged to provide information on the exclusive global unlimited rights that XVIVO Perfusion has to certain media developed by Professor Stig Steen and Vivoline Medical for the evaluation and preservation of organs in connection with transplantation.
Pursuant to the current agreement with Professor Stig Steen and Igelösa Life Science AB, XVIVO Perfusion has global unlimited irrevocable exclusive rights to media and related patents for the preservation and evaluation of organs, media which are based on LPD (low potassium dextran) such as Perfadex®, with added calcium, created by Professor Stig Steen and Vivoline Medical.
Several of Vivoline Medical’s patent rights mentioned in its Memorandum are for media created by Professor Stig Steen for the preservation and evaluation of organs, media which are based on LPD with added calcium. These patents are thus covered by XVIVO Perfusion’s exclusive rights.
XVIVO Perfusion’s product STEEN Solution™ is protected by a patent which is valid until the year 2021 and which covers evaluation and preservation solutions containing LPD in combination with the high concentrations of albumin that are considered necessary to create an effective protective environment for the organs being evaluated and stored.
Magnus Nilsson, CEO of XVIVO Perfusion: “XVIVO Perfusion intends to continue developing and commercializing Professor Stig Steen’s media in the best way possible so as to create value for patients, customers and shareholders.”
April 12, 2013
Gothenburg
XVIVO Perfusion AB (publ)
For further information please contact:
Christoffer Rosenblad, CFO, +46 31 788 21 59, christoffer.rosenblad@xvivoperfusion.com
Xvivo Perfusion is required to publish the information in this press release in accordance with the Swedish Securities Market Act and/or the Financial Instruments Trading Act. The information was submitted for publication on April 12, 2013 at 11:45 a.m.
This is a translation of the Swedish version of the press release. When in doubt, the Swedish wording prevails.
